Dianthus Q3: $1.2B Cash Into 2030, 75% CIDP Response Rate, MMN Data in December
DNTH has more than doubled off its 52-week low of $32.42 on elevated volume (2.0× avg).
Summary
Dianthus reported a $46.6M Q3 net loss with about $1.2 billion of cash funding operations into 2030, and disclosed a 75% interim response rate in its Phase 3 CIDP trial ahead of MMN Phase 2 top-line data in December 2026.
Key Events · Earnings and Guidance · DNTH
-
Q3 Loss Widens on Clinical Spend
Net loss was $46.6 million, or $0.81 per share, versus $36.8 million, or $0.97 per share, a year earlier. R&D rose to $45.6 million from $32.5 million and G&A to $14.1 million from $8.2 million.
-
Cash Funds Runway Into 2030
Cash, cash equivalents and investments totaled approximately $1.2 billion as of September 30, 2026, which management projects provides runway into 2030 — covering the MMN, CIDP and gMG readouts without a near-term raise.
-
CIDP Interim Response Rate Beats Target
A 75% response rate was observed in the interim responder analysis of the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, above the 50%-or-greater target set from precedent aC1s inhibition, with no related serious infections or drug-induced lupus.
-
CAPTIVATE Enrollment Requirement Cut
Part A is now projected to need fewer than 200 participants to randomize 128 responders into Part B. Part A top-line is expected by YE'27 and Part B top-line by YE'28.
Analysis · DNTH · Life Sciences
The quarter itself is unremarkable — a $46.6M net loss on $45.6M of R&D is what a company running two Phase 3 programs should burn. What matters is the clinical readout calendar and the balance sheet behind it. The interim 75% response rate in the first 40 CAPTIVATE patients clears the 50% bar management set from precedent, and the trial can now reach its 128-responder randomization with fewer than 200 patients in Part A, which shortens enrollment risk. The nearest hard event is the Phase 2 MoMeNtum top-line in MMN this December, now with 46 patients rather than the original 36 — a larger dataset than planned. Roughly $1.2 billion of cash funds operations into 2030, so none of the upcoming readouts require a financing decision first. Against that, spending is climbing fast: R&D is up 40% year over year and G&A up 72%, and the loss per share only fell because the share count grew from 37.8M to 57.3M weighted-average.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DNTH was trading at $85.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $32.42 to $117.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.